, Assessment report: vancomcyin containing medicinal products (EMEA/H/A-31/1440). Committee for Medicinal Producst for Human Use, 2017.
Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary, Clin Infect Dis, vol.52, issue.3, pp.285-92, 2011. ,
Vancomycin: a review of population pharmacokinetic analyses, Clin Pharmacokinet, vol.51, issue.1, pp.1-13, 2012. ,
Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions, Lancet Infect Dis, vol.14, issue.6, pp.498-509, 2014. ,
DosOpt: a tool for personalized Bayesian dose adjustment of vancomycin in neonates, Ther Drug Monit, vol.39, issue.6, pp.604-617, 2017. ,
Predictability of vancomycin trough concentrations using seven approaches for estimating pharmacokinetic parameters, Am J Health Syst Pharm, vol.63, issue.23, pp.2365-70, 2006. ,
Population pharmacokinetics of vancomycin in adult and geriatric patients: comparison of eleven approaches, Int J Clin Pharmacol Ther, vol.48, issue.8, pp.525-558, 2010. ,
A general purpose pharmacokinetic model for propofol, Anesth Analg, vol.118, issue.6, pp.1221-1258, 2014. ,
An allometric model of remifentanil pharmacokinetics and pharmacodynamics, Anesthesiology, vol.126, issue.6, pp.1005-1023, 2017. ,
Increasing the utility of targetcontrolled infusions: one model to rule them all, Br J Anaesth, vol.120, issue.5, pp.887-90, 2018. ,
A pharmacokinetic standard for babies and adults, J Pharm Sci, vol.102, issue.9, pp.2941-52, 2013. ,
Scaling clearance in paediatric pharmacokinetics: all models are wrong, which are useful?, Br J Clin Pharmacol, vol.83, issue.4, pp.777-90, 2017. ,
, Clin Pharmacokinet, 2018.
A general model for the origin of allometric scaling laws in biology, Science, vol.276, issue.5309, pp.122-128, 1997. ,
Reference intervals for serum creatinine concentrations: assessment of available data for global application, Clin Chem, vol.54, issue.3, pp.559-66, 2008. ,
Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets, Clin Infect Dis, vol.52, issue.8, pp.975-81, 2011. ,
Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists, Clin Infect Dis, vol.49, issue.3, pp.325-332, 2009. ,
Identification of vancomycin exposure-toxicity thresholds in hospitalized patients receiving intravenous vancomycin, Antimicrob Agents Chemother, pp.1684-1701, 2018. ,
A simplex method for function minimization, Computer J, vol.7, pp.308-321, 1965. ,
Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance, Br J Clin Pharmacol, vol.63, issue.1, pp.75-84, 2007. ,
Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations, J Antimicrob Chemother, vol.63, issue.5, pp.1050-1057, 2009. ,
Influence of erroneous patient records on population pharmacokinetic modeling and individual bayesian estimation, Ther Drug Monit, vol.34, issue.5, pp.526-560, 2012. ,
Vancomycin pharmacokinetics in patients with severe burn injuries, Burns, vol.36, issue.4, pp.469-76, 2010. ,
Vancomycin population pharmacokinetics in neonates, Clin Pharmacol Ther, vol.67, issue.4, pp.360-367, 2000. ,
Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens, Antimicrob Agents Chemother, vol.55, issue.6, pp.2704-2713, 2011. ,
Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections, Pharmacotherapy, vol.35, issue.2, pp.127-166, 2015. ,
Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type, J Clin Pharm Ther, vol.34, issue.4, pp.473-83, 2009. ,
Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation, Br J Clin Pharmacol, vol.70, issue.2, pp.201-213, 2010. ,
Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies, Antimicrob Agents Chemother, vol.49, issue.12, pp.4934-4975, 2005. ,
Vancomycin prescription in neonates and young infants: toward a simplified dosage, Arch Dis Child Fetal Neonatal Ed, vol.96, issue.5, pp.365-70, 2011. ,
New regimen for continuous infusion of vancomycin in critically ill patients, Antimicrob Agents Chemother, vol.60, issue.8, pp.4750-4756, 2016. ,
Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination, Antimicrob Agents Chemother, vol.54, issue.6, pp.2626-2658, 2010. ,
Pharmacokinetics of vancomycin and dosing recommendations for trauma patients, J Antimicrob Chemother, vol.71, issue.2, pp.471-480, 2016. ,
A method for computing profilelikelihood-based confidence-intervals, Appl Stat J R St C, vol.37, issue.1, pp.87-94, 1988. ,
Scaling beta-lactam antimicrobial pharmacokinetics from early life to old age, Br J Clin Pharmacol, 2018. ,
A population pharmacokinetic/pharmacodynamic model of methotrexate and mucositis scores in osteosarcoma, Ther Drug Monit, vol.33, issue.6, pp.711-719, 2011. ,
Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis, Clin Pharmacokinet, vol.52, issue.4, pp.289-301, 2013. ,
Determination of reference intervals for serum creatinine, creatinine excretion and creatinine clearance with an enzymatic and a modified Jaffe method, Clin Chim Acta, vol.344, issue.1-2, pp.137-185, 2004. ,
Development of an optimized pharmacokinetic model of dexmedetomidine using target-controlled infusion in healthy volunteers, Anesthesiology, vol.123, issue.2, pp.357-67, 2015. ,
Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models, AAPS J, vol.13, issue.2, pp.143-51, 2011. ,
Human renal function maturation: a quantitative description using weight and postmenstrual age, Pediatr Nephrol, vol.24, issue.1, pp.67-76, 2009. ,
Clinical pharmacokinetics of vancomycin, Clin Pharmacokinet, vol.11, issue.4, pp.257-82, 1986. ,
Allometric scaling of clearance in paediatric patients: when does the magic of 0.75 fade?, Clin Pharmacokinet, vol.56, issue.3, pp.273-85, 2017. ,
Continuous infusion versus intermittent administration of meropenem in critically ill patients, J Antimicrob Chemother, vol.43, issue.4, pp.523-530, 1999. ,
Different vancomycin immunoassays contribute to the variability in vancomycin trough measurements in neonates, Biomed Res Int, 2016. ,
Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population, J Oncol Pharm Pract, vol.18, issue.1, pp.91-97, 2012. ,
Population pharmacokinetics and dosing optimization of vancomycin in children with malignant hematological disease, Antimicrob Agents Chemother, vol.58, issue.6, pp.3191-3200, 2014. ,
The phenomenon and rationale of marked dependence of drug concentration on blood sampling site. Implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics (Part I), Clin Pharmacokinet, vol.17, issue.3, pp.175-99, 1989. ,